Award
National Institute of Neurological Disorders and Stroke 1R41NS143585-01
Development and Validation of Efficacy Biomarkers for QTE Therapy in Friedreich's Ataxia
Recipient
ANEKABIO LLC
Award Amount
$454,437.00
Ceiling
$454,437.00
Awarded
September 23, 2025
Identifier
1R41NS143585-01
AnekaBio, LLC is awarded $454,437 by the National Institute of Neurological Disorders and Stroke to develop and validate biomarkers for QTE therapy in Friedreich's Ataxia, aiming to improve treatment efficacy and safety and advance clinical trials.
Description
This project aims to identify and validate efficacy biomarkers for QTE therapy in Friedreich's Ataxia, focusing on improving treatment outcomes and advancing toward clinical trials. The therapy is an innovative multi-targeted approach that has shown superior preclinical results compared to existing treatments, with the goal of transitioning to clinical trials.